News for Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)

Published at

May 22, 2025 3:00 PM

by gurufocus.com

positive

positive

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”Corbus” or the ”Company”), today announced that Yuval

CRBP 0SZI.L

Read more →
Published at

May 19, 2025 3:33 PM

by gurufocus.com

neutral

neutral

Corbus Pharmaceuticals (CRBP) Names New Chair to Board of Directors | CRBP Stock News

Corbus Pharmaceuticals (CRBP) has appointed Rachelle Jacques to lead its Board of Directors, starting from May 15. Jacques takes over the role from Alan Holmer,

CRBP 0SZI.L

Read more →
Published at

May 19, 2025 3:00 PM

by gurufocus.com

mixed

mixed

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( CRBP), a clinical-stage company focused on oncology and obesity, today

CRBP AKTX 0SZI.L UQ1.DE QURE 0EE0.L

Read more →
Published at

May 7, 2025 3:21 PM

by gurufocus.com

neutral

neutral

Oppenheimer Adjusts Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News

Oppenheimer has revised its price target for Corbus Pharmaceuticals (CRBP), reducing it from $60 to $56. Despite this adjustment, the firm continues to rate the

CRBP 0SZI.L

Read more →
Published at

May 7, 2025 1:31 PM

by gurufocus.com

neutral

neutral

Corbus Pharmaceuticals (CRBP) Sees Price Target Reduction | CRBP Stock News

H.C. Wainwright has adjusted its price target for Corbus Pharmaceuticals (CRBP), dropping it to $40 from a previous $50, while maintaining a Buy rating on the s

CRBP 0SZI.L

Read more →
Published at

May 6, 2025 3:34 PM

by gurufocus.com

neutral

neutral

Corbus Pharmaceuticals (CRBP) Advances Pipeline with Promising Early Trial Data | CRBP Stock News

In the first quarter of 2025, Corbus Pharmaceuticals (CRBP) made significant strides in its drug development pipeline. The company showcased promising Phase 1 r

CRBP 0SZI.L

Read more →
Published at

May 6, 2025 3:00 PM

by gurufocus.com

neutral

neutral

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on sc

CRBP 0SZI.L

Read more →
Published at

May 6, 2025 2:15 PM

by manilatimes.net

neutral

neutral

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

**media[615860]**

CRBP 0SZI.L

Read more →
Published at

Mar 28, 2025 2:00 PM

by gurufocus.com

neutral

neutral

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimon

CRBP 0SZI.L

Read more →
Published at

Mar 11, 2025 2:00 PM

by gurufocus.com

neutral

neutral

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic

CRBP 0SZI.L

Read more →
Published at

Feb 25, 2025 3:00 PM

by gurufocus.com

positive

positive

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”Corbus” or the ”Company”), today announced that Yuva

CRBP 0SZI.L

Read more →
Published at

Feb 25, 2025 2:13 PM

by manilatimes.net

positive

positive

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

**media[549724]**

CRBP COWNL COWN 0SZI.L

Read more →
Published at

Feb 15, 2025 11:23 AM

by gurufocus.com

positive

positive

Orbimed Advisors LLC Reduces Stake in Corbus Pharmaceuticals Holdings Inc

On December 31, 2024, Orbimed Advisors LLC executed a significant transaction involving Corbus Pharmaceuticals Holdings Inc (CRBP). The firm reduced its holding

ISRG.MX ISRG CRBP 0SZI.L 0R29.L

Read more →
Published at

Feb 14, 2025 1:47 PM

by manilatimes.net

mixed

mixed

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

**media[540758]**

0SZI.L CRBP

Read more →
Published at

Feb 11, 2025 1:34 PM

by manilatimes.net

positive

positive

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

**media[537519]**

CRBP 0SZI.L

Read more →
Published at

Jan 28, 2025 2:11 PM

by manilatimes.net

neutral

neutral

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

**media[526211]**

CRBP 0SZI.L

Read more →
Published at

Jan 6, 2025 2:00 PM

by gurufocus.com

neutral

neutral

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”Corbus” or the ”Company”), today announced that Yuva

CRBP 0SZI.L

Read more →
Published at

Dec 9, 2024 1:21 PM

by manilatimes.net

positive

positive

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

**media[486994]**

CRBP 0SZI.L

Read more →
Published at

Dec 9, 2024 1:00 PM

by gurufocus.com

positive

positive

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRB-601 is an anti-Î±vÎ²8 monoclonal antibody designed to block activation of latent TGFÎ² in the tumor micro-environment NORWOOD, Mass., Dec. 09, 2024 (GLO

CRBP 0SZI.L

Read more →
Published at

Dec 4, 2024 6:31 PM

by insidermonkey.com

positive

positive

Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Corbus Pharmaceuticals Holdings...

CRBP 0SZI.L

Read more →